Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 25, 2025

5 Beloved Stocks on Wall Street I'd Sell Right Now

View original at nasdaq.com
5 Beloved Stocks on Wall Street I'd Sell Right Now Key Points Investors have every reason to smile, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, respectively, climbing by 14% to 20% year-to-date…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Palantir's AI and machine learning-driven platforms Gotham and Foundry aren't duplicable at scale

    80% confidence

  • Beyond Meat experienced higher trade discounts and price decreases of certain products in Q3

    80% confidence

  • Tesla sales expected to fall by 3% in 2025 based on Wall Street consensus

    80% confidence

  • Large public companies with price-to-sales ratios above 30 have historically signaled the presence of a bubble since the mid-1990s

    80% confidence

  • Entering 2026 with the second priciest stock market dating back to January 1871

    80% confidence

  • Palantir's P/S ratio of almost 127 represents an inexplicably high valuation that is historically unsustainable

    80% confidence

  • Elon Musk's annual claim of Level 5 autonomy being 'one year away' has surpassed the decade mark

    80% confidence

  • Bitcoin's real-world utility test didn't go very well in El Salvador

    80% confidence

  • 40% to 50% or more of Tesla's quarterly pre-tax income has originated from automotive regulatory credits and net interest income on its cash

    80% confidence

Data points we hold from this source

Apple Podcasts · price to earnings ratio33 ratio
Apple Podcasts · share buyback total816 billion_USD
Apple Podcasts · shares repurchased44 percent
Apple Podcasts · net income112 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
5 Beloved Stocks on Wall Street I'd Sell Right Now — Source | Via News | Finance Via News